Aptosyn exisulind: Completed Phase II trial enrollment

Cell Pathways Inc. (CLPA), Horsham, Penn. Product: Aptosyn exisulind Business: Cancer Therapeutic category: Apoptosis Target: cGMP-PDE Description: Oral sulfone metabolite of sulindac that augments ap...